2017 ANNUAL REPORT

Included in the 2017 Annual Report: Form 10-K filed with the U.S. Securities and Exchange Commission

Dated April 2, 2018

CORPORATE INFORMATION

Directors Uli Hacksell, Ph.D., Chairman Isaac Blech, Vice Chairman Steven J. Boyd Chief Investment Officer, Armistice Capital Peter Greenleaf Phil Gutry Executive Director, Business Development, Regeneron Pharmaceuticals, Inc. Randal O. Jones President, Fremantle Corporation Robert C. Moscato, Jr. Magnus Persson, M.D., Ph.D. Chief Executive Officer of Karolinska Institutet Holding AB Associate Professor in Physiology, Karolinska Institutet Pediatrician, CityAkuten Officers Peter Greenleaf Chief Executive Officer and Director Mr. Greenleaf has been our Chief Executive Officer since March 2018 and has been a member of our Board since May 2017. Until February 2018, Mr. Greenleaf served as Chief Executive Officer and is a member of the board of directors of Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP), positions he held since March 2014. Sucampo was focused on the development and commercialization of medicines to meet major unmet medical needs of patients worldwide and was sold in February 2018 to U.K. pharmaceutical giant Mallincrodt PLC. From June 2013 to March 2014, Mr. Greenleaf served as Chief Executive Officer and a member of the board of directors of Histogenics Corporation, a regenerative medicine company. From 2006 to 2013, Mr. Greenleaf was employed by MedImmune LLC, the global biologics arm of AstraZeneca, where he most recently served as President. From January 2010 to June 2013, Mr. Greenleaf also served as President of MedImmune Ventures, a wholly owned venture capital fund within the AstraZeneca Group. Prior to serving as President of MedImmune, Mr. Greenleaf was Senior Vice President, Commercial Operations of the company, responsible for its commercial, corporate development and strategy functions. Mr. Greenleaf has also held senior commercial roles at Centocor Biotech, Inc. (now Jansen Biotechnology, Johnson & Johnson) from 1998 to 2006, and at Boehringer Mannheim G.m.b.H. (now Roche Holdings) from 1996 to 1998. Mr. Greenleaf currently chairs the Maryland Venture Fund Authority, whose vision is to oversee implementation of InvestMaryland, a public-private partnership to spur venture capital investment in the state. He is also a member of the board of directors of the Biotechnology Industry Organization (BIO), where he serves on the Governing Boards of the Emerging Companies and Health Sections. Mr. Greenleaf earned a M.B.A degree from St. Joseph’s University and a B.S. degree from Western Connecticut State University.

Mariam E. Morris, CPA Chief Financial Officer Ms. Morris has served as our Chief Financial Officer since August 2015 and previously served as our interim Chief Financial Officer from May 2015 to August 2015. Prior to joining Cerecor, Ms. Morris was the sole proprietor of Mariam Morris CPA, a full-service tax, accounting and business consulting firm, which she founded in January 2009 and operated until August 2015. Previously, Ms. Morris was the Chief Financial Officer of Sucampo Pharmaceuticals, Inc. from February 2004 to July 2009. From 1991 until 2001, Ms. Morris was an auditor for PricewaterhouseCoopers. Ms. Morris received her B.B.A. in Accounting from Texas Tech University and her M.S. in Taxation from Old Dominion University. Ms. Morris is a Certified Public Accountant in the State of Texas. Matthew V. Phillips Chief Commercial Officer Mr. Phillips is responsible for strategic development and tactical execution of the Company's franchise of prescription medications and dietary supplements. Previously, Mr. Phillips served in various roles of increasing responsibility with Zylera Pharma Corp, where he most recently served as President. Prior, Mr. Phillips was an integral member of the management teams at Victory Pharma, Dura Pharmaceuticals, Inc. and Eisai Co, Ltd. Mr. Phillips earned his bachelor's degree in Business from Central Michigan University. Headquarters 400 East Pratt Street, Suite 606 Baltimore, Maryland 21202 410.522.8707

Transfer Agent American Stock Transfer & Trust Company, LLC 6201 15

th Avenue

Brooklyn, New York 11219 718.921.8217

Website www.cerecor.com

Stock Listing

Cerecor, Inc. common stock and Class A warrants are listed on the Nasdaq Capital Market and quoted under the symbols “CERC” and “CERCW,” respectively.

- � �

☐

-

-

-

Title of each class Name of each exchange on which registered

-

- ☐ �

☐ �

� ☐

- � ☐

-

- - ☐ -

-

☐ ☐ - ☐

� �

�

- ☐ �

-

-

i

F-1F-1

ii

-

-

- --

-

- -

-

-

-

1

- --

- - - -

- - - -

-

-

-

- -- - -

-

-

- - -

- - - - - - -- - -

-- -

- -

2

- -

- -

-

-

- - - -

-

3

-

-

-

- -

- -

-

4

- -

-

-

- -

--

-

-

5

-

-

-

-

-

- -

- -

-

-

-

- -

- --

--

- --

-

--

-

-

-

-

-

-

6

-

--

-

- -

-

- -

- --

-

- - --

-

-

-

7

-

-

- -

-

- - - -

-

--

-

-

-

8

-

-

-- -

-

-

- -

-

-

-

-

- -

9

-

-- - - - -

- - - -

-

-

-

-

- - - -

-- -

-

10

-

- - - - --

- - -

- - -

- - - -

- -

- - - -

- -

- -

-

11

-

-

-

12

- - - -

- - --

-

-

-

--

- - - - -

-

-

13

-

-

- - --

- -

-

14

-

15

-

-

-

16

-

-

-

-

17

-

-

-

-

-

-

--

18

-

-

-

- -

19

-

-

-

-

-

--

20

-

-

21

- -

-

-

-

-

22

- -

-

23

- -

- -

-

-

-

- -

-

-

- -

-

24

-

-

-

-

25

26

-

- -

- -

- - -

27

- -

-

28

-

29

-

-

-

- -

- - -

--

-

30

-

- -

- - -- -

-

-- -

31

-

-

-

-

32

-

-

- --

-

--

-

--

-

33

--

-

-

34

35

-

-

36

-

-

-

- -

-

37

-

-

-

-

-

-

38

- - -

-

-

39

--

- --

40

-

41

-

- -

-

--

-

42

-

43

-

44

-

45

-

-

-

- --

46

-

-

-

47

- - -

-

-

--

48

-

-

-

-

-

-

49

- -

--

-

-

- --

--

- -

50

-

51

- -

-

-

52

-

- -

-

-

53

--

--

-

- -

54

-

-

-

55

-

-

-

- -

--

- -

56

-

- -

-

-

57

- -

-

-

-

-

58

59

-

-

60

61

-

62

-

-

-

-

63

-

64

-

---

-

-

-

-

-- - -

-

-

-

- -- - -

--

-

- - -- - - - - - - - -

-

- --

-

65

--

- - -- -

-

- -

-

-

-

66

-

- - - -

-

-

-

--

-

67

-

-

-

- -

-

68

-- -

-

-

-

-

69

-

- -

- -

- -

70

71

-

-

- - -

72

- -

- -

-

-

--

-

-- - -

- -

-

-

-

-

-

73

-

-

-

-

--

-

74

-

-

-

-

--

- --

--

-

-

--

-

75

-

76

-

-

-

-

-

-

--

-

-- - -

-

77

-

-

-

-

--

-

78

-

- -

-

79

- -

- - -

-

- -

80

-

-

--

--

-

- -

-

-

-

81

-

-

(1)

(2)

(3)

-

-

-

-

82

-

-

-

-

-

- -

- -- -

-

83

- -

-

-

- -

- -

84

-

-

-

85

-

-

(This page has been left blank intentionally.)

-1

(a)

1.

2.

3. -

(b)

-

-

-

-

-

-

-

F-8F-9

F-10

F-11F-12F-14

-2

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-3

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-4

-

-

--

-

-

-

-

-

-

-

-

-

-

-5

-

-

-6

-7

-8

-9

-

-

-10

-

-

-

-

-

-

-

-

-11

-12

-13

-

-

-

-

-14

- -

-

- - -

--

--

-

-

-15

-

- -

-

-

-

-

- -

--

--

-

--

-

-16

-

-

- -- -

- -

-17

-

- - -

- -

-

-18

- -- -

-

-

-19

-

--

-

-

-20

-

- -

- -

--

- -

-

- -- -

-

-21

-

-

-

--

-

- - -

-

-

-

--

-

- -

--

-

-22

-

-

- - -

-- - -

- -- - - -

-- - - - -

- - -

- -- - -

--

--

-

- -

- --

- -

- - --

-23

-

- -

-

- - -- -

-24

-

-

-

-

-25

-

-

-

-

-26

--

-

-

-

-

-

-

-27

-

- -

- -

- -

-28

- -- -

- -

- -

-

-29

-30

-

-- - - - - - - - -

-

-

-

-

-31

- - - -

--

-

--

- - - - - -

- - -

- -

- - - -- -

- -

-

-32

-

-

-

-33

-

--

-

--

-34

- --

-

-

-

-35

-

-36

-

--

--

- -

-

-37

- -

-

-

- -

-

-38

-

- -- -

-

-39

-

-40

-

--

-

-

-41

-42

-

-

-

-

-43

(This page has been left blank intentionally.)

400 East Pratt Street, Suite 606 Baltimore, Maryland 21202

Phone: 410.522.8707 www.cerecor.com